Browsing Bergen Open Research Archive by Author "Brümmendorf, Tim H."
Now showing items 1-2 of 2
-
Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line
Kreutzman, Anna; Yadav, Bhagwan; Brümmendorf, Tim H.; Gjertsen, Bjørn Tore; Lee, Moon Hee; Janssen, Jeroen; Kasanen, Tiina; Koskenvesa, Perttu; Lofti, Kourosh; Markevärn, Berit; Olsson-Strömberg, Ulla; Stentoft, Jesper; Stenke, Leif; Söderlund, Stina; Udby, Lene; Richter, Johan; Hjorth-Hansen, Henrik; Mustjoki, Satu (Journal article; Peer reviewed, 2019)Changes in the immune system induced by tyrosine kinase inhibitors (TKI) have been shown to positively correlate with therapy responses in chronic myeloid leukemia (CML). However, only a few longitudinal studies exist and ... -
Impact of age and comorbidities on the efficacy and tolerability of bosutinib in previously treated patients with chronic myeloid leukemia: results from the phase 4 BYOND study
Rosti, Gianantonio; Brümmendorf, Tim H.; Gjertsen, Bjørn Tore; Giraldo-Castellano, Pilar; Castagnetti, Fausto; Gambacorti-Passerini, Carlo; Ernst, Thomas; Zhao, Huadong; Kuttschreuter, Luke; Purcell, Simon; Giles, Francis J.; Hochhaus, Andreas (Journal article; Peer reviewed, 2024)In the phase 4 BYOND trial, patients with pretreated chronic myeloid leukemia (CML) received bosutinib (starting dose: 500 mg/day). Efficacy and safety after ≥3 years of follow-up in 156 patients with Philadelphia ...